Bayer HealthCare and Onyx Pharmaceuticals, Inc., United States, have restructured their partnership for the global development and marketing of Nexavar™ (active ingredient: sorafenib) and entered into a new agreement concerning regorafenib. Further details are explained in the Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group under
“Legal Risks.”In October 2011, the deadline – originally due to expire in October 2011 – for U.S. rice growers to submit their claims under settlement agreements in the litigation concerning genetically modified rice (LL RICE) was extended by 40 days. Further details are explained in the Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group under
“Legal Risks.”In October 2011, Bayer CropScience acquired the oilseed rape business of the mid-size seed company Raps GbR, Germany. This mainly includes oilseed rape varieties that are already on the market and the company’s breeding material. The agreed purchase price of €27 million pertains mainly to technologies, inventories and goodwill.